CytomX Therapeutics (CTMX) announced the appointment of Rachael Lester as senior VP, chief business officer. In this role, Lester will lead the company’s strategy and business development functions. Lester joins CytomX with over two decades leading corporate strategy, business development and product portfolio planning across the life science and biopharmaceutical industry. Most recently, she was chief business officer at Replicate Bioscience.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- Oppenheimer positive on CytomX after Merus colon cancer data
- CytomX Therapeutics: Hold Rating Amid Awaited CX-801 Data and Market Potential
- CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
- CytomX Therapeutics assumed with an Overweight at Barclays
- CytomX Therapeutics initiated with an Overweight at Barclays